Get the Stockscreener App
34.87
3.00%
1.015
After Hours:
35.20
0.335
+0.96%
Structure Therapeutics Inc Adr stock is traded at $34.87, with a volume of 657.01K.
It is up +3.00% in the last 24 hours and up +15.95% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$33.85
Open:
$34
24h Volume:
657.01K
Relative Volume:
0.66
Market Cap:
$2.01B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-15.70
EPS:
-2.22
Net Cash Flow:
$-105.32M
1W Performance:
+2.51%
1M Performance:
+15.95%
6M Performance:
+36.35%
1Y Performance:
-9.91%
1-Day Range:
$34.00
$35.16
1-Week Range:
$30.95
$35.16
52-Week Range:
$13.22
$38.67
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(650) 457-1978
Address
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
34.87 | 2.06B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.22 | 106.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
674.55 | 68.81B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.95 | 58.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
889.64 | 53.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.69 | 40.93B | 447.02M | -1.18B | -906.14M | -6.1812 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | Citigroup | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Structure Therapeutics Reports Q3 2025 Financial Results - TipRanks
Buy Rating for Structure Therapeutics: Potential Breakthrough in Obesity Treatment with Aleniglipron - TipRanks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zymeworks (ZYME), MBX Biosciences, Inc. (MBX) and Lemaitre Vascular (LMAT) - The Globe and Mail
Decoding Structure Therapeutics Inc (GPCR): A Strategic SWOT Ins - GuruFocus
Positive Buy Rating for Structure Therapeutics Driven by Promising Product Outlook and Strong Financial Position - TipRanks
Structure Therapeutics : Corporate Presentation (November 2025) - MarketScreener
Entero Therapeutics’ Board Governance Structure Update - TipRanks
[8-K] Structure Therapeutics Inc. Reports Material Event | GPCR SEC FilingForm 8-K - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) on track for 36-week GLP-1 data year-end 2025 - Stock Titan
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights - The Globe and Mail
CapEx per share of Structure Therapeutics, Inc. Sponsored ADR – NASDAQ:GPCR - TradingView
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Wall Street analysts’ outlook for Structure Therapeutics Inc ADR (GPCR) - setenews.com
Structure Therapeutics (GPCR) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Pier Capital LLC Cuts Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Up 9.2%Still a Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Tectonic Therapeutic (TECX) and Akebia Therapeutics (AKBA) - The Globe and Mail
Strong Market Demand and Convenience Drive Buy Rating for Structure Therapeutics - TipRanks
11,000 Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR Acquired by Allianz Asset Management GmbH - MarketBeat
Allianz Asset Management GmbH Has $252,000 Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - Defense World
Allianz Asset Management GmbH Purchases New Holdings in Tarsus Pharmaceuticals, Inc. $TARS - Defense World
Jazz Pharmaceuticals (NASDAQ: JAZZ) names Ted W. Love, M.D., to board Dec 1, 2025 - Stock Titan
Structure Therapeutics (NASDAQ:GPCR) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now? - NewsBreak: Local News & Alerts
Critical Survey: Alkermes (NASDAQ:ALKS) and Structure Therapeutics (NASDAQ:GPCR) - Defense World
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Kura Oncology (KURA) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Align Tech (ALGN) and ProQR (PRQR) - The Globe and Mail
Pacific Heights Asset Management LLC Acquires New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Trading Systems Reacting to (GPCR) Volatility - news.stocktradersdaily.com
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Wuxi Biologics (Cayman) (OtherWXIBF) and Avalo Therapeutics (AVTX) - The Globe and Mail
(PDF) Structural basis for chemotype diversity in small molecule GLP-1 receptor agonist drug discovery - researchgate.net
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cigna (CI), Abbott Laboratories (ABT) and Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Aclaris Therapeutics (ACRS) - The Globe and Mail
Aberdeen Group plc Raises Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Inc. (GPCR): Investor Outlook With A 142% Potential Upside - DirectorsTalk Interviews
Griffin Asset Management Inc. Makes New Investment in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Target Price at $68.67 - Defense World
Brokerages Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) PT at $68.67 - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Structure Therapeutics' (GPCR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Purchased by Signaturefd LLC - Defense World
Piper Sandler Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Citius Oncology (NASDAQ:CTOR) and Structure Therapeutics (NASDAQ:GPCR) Head to Head Survey - Defense World
Structure Therapeutics (NASDAQ:GPCR) Trading Down 4.3%Should You Sell? - MarketBeat
ABSSSI Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Glenmark Pharma, Melinta Therapeutics, Sandoz Inc, Paratek Pharma, AbbVie Inc., Allergan PLC, Merck & Co. Inc., Pfizer - The Globe and Mail
ABSSSI Market to Reach New Heights in Growth by 2034, - openPR.com
Structure Therapeutics (NASDAQ:GPCR) Trading 5.8% HigherTime to Buy? - MarketBeat
ETFs Investing in Structure Therapeutics, Inc. Sponsored ADR Stocks - TradingView
Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense - The Globe and Mail
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):